New Horizon Health HK$2.04 billion IPO
We advised New Horizon Health on its IPO and HKEX listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Akeso HK$1.19 billion share placement
We advised the placing agent in the placement of new shares
Ocumension Therapeutics HK$793.8 million top-up placement of shares
We advised the placing agent in connection with the equity offering
Ronshine China Holdings $200 million high-yield notes offering
We advised the initial purchasers on the Regulation S offering
Venus Medtech HK$1.4 billion placing of new H shares
We advised Venus Medtech (Hangzhou) on its placement of new shares
Innovent Biologics HK$4.73 billion placement of shares
We advised the joint placing agents in connection with the equity offering
Ronshine China Holdings $300 million high-yield notes offering
We advised the initial purchaser on the Regulation S offering
China South City Holdings $120 million high-yield notes reopening
We advised the initial purchasers on the Regulation S offering
Dexin China Holdings $150 million high-yield notes reopening
We advised the initial purchasers on the Regulation S offering
Fantasia Holdings Group $150 million high-yield notes offering
Davis Polk advised the initial purchasers in connection with a Regulation S offering of $150 million 6.950% senior notes due 2021 by Fantasia Holdings Group Co., Limited on December 18,…